Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention

Frontiers in Immunology(2023)10.3389/fimmu.2023.1036563Source: DataRank Database

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention is a research paper published in Frontiers in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.45)OA: goldTopics (65)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Donghai Xiong ORCID,Qi Zhang ORCID,Katie Palen,Robert H. Shoemaker ORCID,Bryon D. Johnson ORCID

Live enrichment

PubMed:36875137 OpenAlex:https://openalex.org/W4321233916

National Institutes of Health

Grant: 5R01CA223804-03

Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer

National Institutes of Health

Grant: 5R01CA205633-02

Inhibition of Oral Tumorigenesis by Antitumor B

National Institutes of Health

Grant: 1R01CA232433-01A1

Chemoprevention of lung cancer by targeting lonidamine to mitochondria

National Institutes of Health

Grant: 5R01CA208648-03

Chemoprevention of lung cancer with mitochondria-targeted honokiol

NCI NIH HHS

Grant: R01 CA223804

NCI NIH HHS

Grant: R01 CA232433

NCI NIH HHS

Grant: R01 CA208648

FWCI

0.45

Citation Percentile

0.6%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.3389/fimmu.2023.1036563

publisherhttps://doi.org/10.3389/fimmu.2023.1036563

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1036563/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36875137

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9982083

Fields of Study

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research0301 basic medicine0303 health sciences03 medical and health sciencesHumansAnimalsMiceErbB ReceptorsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationProtein Kinase InhibitorsNeoplasm Recurrence, LocalCarcinogenesisCell Transformation, NeoplasticTumor Microenvironment

MeSH Terms

AnimalsCarcinoma, Non-Small-Cell LungCell Transformation, NeoplasticHumansLung NeoplasmsMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsMiceTumor MicroenvironmentCarcinogenesisErbB Receptors

Keywords

Epidermal growth factor receptorCancer researchCarcinogenesisT790MLung cancerMutationImmune systemImmunotherapyMedicineBiologyImmunologyCancerOncologyInternal medicineGeneGefitinibGeneticsLung NeoplasmsT cellimmunointerceptionRC581-607ErbB ReceptorsMiceCell Transformation, NeoplasticCarcinoma, Non-Small-Cell Lungprecision immunopreventionpeptide vaccineMHC class IITumor MicroenvironmentHumansAnimalsEGFR mutationImmunologic diseases. AllergyNeoplasm Recurrence, LocalProtein Kinase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being